---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-000317"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2024-01-02T23:59:59+00:00"
generated_at: "2026-06-07T05:20:46.296747+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics closes $3.5M public offering of common stock and warrants

## Summary
- 2,692,308 units sold at $1.30/unit: one share (or pre-funded warrant) plus one warrant to buy one share.
- Gross proceeds ~$3.5M; net proceeds to fund FDA approval, clinical studies, R&D, and working capital.
- Warrants exercisable at $1.30/share for 5 years; pre-funded warrants exercisable at $0.0001.
- H.C. Wainwright as placement agent; 7% cash fee and 188,462 placement agent warrants at $1.625.
- Offering closed Jan 2, 2024; registered on Form S-1 effective Dec 27, 2023.

## SEC filing metadata
- accession: 0001213900-24-000317
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2024-01-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390024000317/0001213900-24-000317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390024000317/ea191005-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-000317
- JSON: https://secwatch.observer/filing/0001213900-24-000317.json
- Plain text: https://secwatch.observer/filing/0001213900-24-000317.txt

## Key facts
- Material Agreements
  Bluejay Diagnostics, Inc. entered into Purchase Agreement with certain institutional investors (effective 2023-12-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Effective: 2023-12-27
  source text: On December 27, 2023, Bluejay Diagnostics, Inc. (the “Company”) commenced a public offering (such transaction, the “Offering”) for the issuance and sale of (i) 537,768 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”) and (ii) prefunded warrants to purchase up to an aggregate 2,154,540 shares of Common Stock (the “Prefunded Warrants”). The Shares and Prefunded Warrants were sold together with warrants to purchase up to an aggregate of 2,692,308 shares of Common Stock at an exercise price of $1.30 per share (the “Warrants”). Certain institutional investors purchasing securities as part of the offering entered into a securities purchase agreement with the Company (the “Purchase Agreement”), dated as of December 27, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390024000317/0001213900-24-000317-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.